Biologics Development Survival Checklist: Helping Great Teams Discover Successful Biotherapeutics

Biologics Development Survival Checklist

Promising biologics don’t fail because teams lack expertise and drive. More often, programs stall because a critical risk, whether it be regulatory, safety-related, or manufacturing, was identified too late.

So, how do you survive these late-stage issues? In short, start derisking early. Below, we’ve developed a survival checklist for your biologics development program to help you focus on what matters. The following 5 priorities can help teams anticipate problems, generate more decision-ready data, and give strong candidates a better chance of reaching patients.

1. Engage Regulators Early

Regulatory conversations should begin before pivotal decisions become difficult or expensive to change. Early engagement can clarify expectations for study designs, safety packages, manufacturing controls, endpoints, and biomarkers, particularly for newer modalities such as antibody-drug conjugates (ADCs) and multispecific antibodies.

A rigorous preclinical package makes these discussions more productive. Teams should also account for differences across different regulatory bodies rather than assuming that a single development strategy will satisfy them all.

2. Make Safety Mechanistic

Safety assessment begins with understanding the mechanism of action (MoA). A clearly defined MoA helps teams distinguish anticipated pharmacology from unexpected toxicity and informs dose selection, biomarker strategies, and clinical monitoring.

For antibodies, this includes characterizing effector functions such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), as well as FcγR, FcRn, and C1q binding. Immunogenicity risks, including anti-drug antibodies, loss of efficacy, and hypersensitivity, should also be investigated early through complementary binding, functional, and immune-activation assays.

3. Examine Specificity from Every Angle

Low overall sequence homology between the intended target and related human proteins does not necessarily rule out off-target binding. If a related protein shares sequence or structural similarity within the antibody’s specific epitope, the antibody may still recognize it.

Developers should therefore map the epitope, compare that region across related human proteins, and confirm selectivity using complementary binding and functional assays.

Cross-species epitope conservation should also be assessed to determine whether the antibody recognizes the corresponding target in the animal species selected for toxicology studies. Separately, tissue expression studies can identify healthy tissues that express the intended target and may therefore be vulnerable to on-target, “off-tissue” effects.

4. Plan for the Product, Not Just the Molecule

A biologically compelling molecule must still be manufactured, stored, transported, and administered reliably. Assess expression yield, aggregation, stability, formulation requirements, and process scalability while candidate selection is still underway.

Logistics deserve equal attention. Can the product tolerate refrigeration, freezing, agitation, temperature fluctuations, and repeated handling? Stress and stability studies that reflect real shipping conditions can reveal risks that ideal laboratory storage may conceal.

5. Protect the Team Behind the Program

Biotherapeutic development is a marathon, and exhausted teams make poorer decisions. Encourage people to flag questionable data and emerging risks early. Foster mental wellness, maintain perspective when experiments disappoint, and recognize the value of small gestures that sustain morale.

Yes, that includes good coffee and a well-stocked snack drawer. Your molecule cannot survive without the people developing it.

At Eurofins Discovery, we support biotherapeutic programs with integrated capabilities for characterization, safety, immunogenicity, specificity, and translational services.